Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed
Aliment Pharmacol Ther
.
2019 Mar;49(6):816-817.
doi: 10.1111/apt.15081.
Authors
David J Gibson
1
,
Mark G Ward
1
Affiliation
1
Gastroenterology, Alfred Hospital, Melbourne, Vic., Australia.
PMID:
30811645
DOI:
10.1111/apt.15081
No abstract available
Publication types
Editorial
Comment
MeSH terms
Drug Monitoring*
Gastrointestinal Agents
Humans
Inflammatory Bowel Diseases*
Infliximab
Patients
Recurrence
Substances
Gastrointestinal Agents
Infliximab